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Cardiomyopathies are primary disorders of heart muscle associated 
with left ventricular dysfunction and development of heart failure, 
in which the heart muscle is structurally and functionally abnormal 
in the absence of significant coronary artery disease, hypertension, 
valvular disease, pericardial disease or congenital heart disease 
sufficient to explain the observed myocardial abnormality.1 In sub-
Saharan Africa (SSA), dilated cardiomyopathy (DCM)  accounts for 
10 - 17% of all cardiac conditions encountered at autopsy, and for 17  - 
48% of hospitalisations for heart failure.2,3 
The Heart of Soweto study (a contemporary study examining the 
characteristics and burden of cardiovascular disease in urban Africa) 
indicates that heart failure is the commonest cardiovascular diagnosis, 
with moderate to severe left ventricular dysfunction present in 53% 
of cases, and 68% of patients with heart failure diagnosed with DCM 
or hypertensive heart disease.4 While DCM occurs at any age, it is 
most common in the 3rd and 4th decades of life, with men affected 
twice as often as women. Two-thirds of patients with DCM, especially 
those over 55 years of age, have persistently low arterial pressure, 
ventricular arrhythmias and/or atrioventricular valve incompetence 
and die within 5 years of their first symptom.5 To the best of our 
knowledge, with the exception of peripartum cardiomyopathy6 there 
are no studies of the outcome of DCM in a contemporary African 
setting. 
While many cases of DCM are thought to be sporadic or acquired, 
in up to 50% of cases the disease is inherited and is termed familial 
DCM.7 Familial DCM is principally caused by mutations in genes 
encoding cytoskeletal, nuclear and sarcomeric proteins in the cardiac 
myocyte, often presenting with incomplete penetrance, variable 
expression and significant locus and allelic heterogeneity.8 Modifying 
genes, lifestyle and additional factors are reported to influence onset 
of disease, disease progression and prognosis in familial DCM. It is 
of clinical interest to know whether the clinical characteristics and 
treatment modalities influence outcome in patients with familial 
DCM, and whether there are differences in clinical characteristics 
and outcome between those with familial and idiopathic DCM.
The purpose of this study was to compare the clinical characteristics 
and outcome of patients with familial and idiopathic DCM in 
a contemporary African setting with access to the full range of 
proven medical and surgical interventions for heart failure, such as 
cardiac resynchronisation therapy and heart transplantation, that are 
available at Groote Schuur Hospital (GSH) in Cape Town.9
Methods
We reviewed the medical records of all patients diagnosed with 
familial and idiopathic DCM and evaluated at the GSH Cardiac 
Clinic from 1 February 1996 to 31 December 2009. The patients 
were seen in a dedicated cardiomyopathy clinic, where one of the 
authors (BMM) has a special interest in disorders of heart muscle, 
and do not reflect the total experience of the GSH Cardiac Clinic. 
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Background. It is not known whether there are differences in 
clinical characteristics and outcomes of patients with familial and 
idiopathic dilated cardiomyopathy (DCM) in an African setting.
Purpose. To compare the clinical characteristics and outcomes of 
familial and idiopathic DCM.
Methods. We performed a retrospective study of familial and 
idiopathic DCM at Groote Schuur Hospital, Cape Town, between 1 
February 1996 and 31 December 2009. Clinical, electrocardiographic 
(ECG) and imaging characteristics were compared, in addition to 
treatment and survival.
Results. Eighty patients with idiopathic DCM and 40 familial 
cases were studied. ECG T-wave inversion was significantly more 
frequent in familial DCM (87.5%) than in idiopathic cases (68.8%) 
(p=0.014), whereas idiopathic patients had a higher prevalence of 
pathological Q waves (32.5%) than familial cases (12.5%) (p=0.028). 
Cardiac chambers were significantly more dilated with poorer 
systolic function in idiopathic than familial cases. A mortality rate 
of 40% after a median follow-up of 5 years was, however, similar 
in both groups. The presence of New York Heart Association 
functional class III and IV symptoms was an independent predictor 
of mortality (odds ratio (OR) 3.85, 95% confidence interval 
(CI) 1.30 - 48.47, p<0.001), while heart transplantation was an 
independent predictor of survival (OR 4.72, 95% CI 1.31 - 72.60, 
p=0.026) in both groups. Digoxin use without serum monitoring 
was a significant predictor of mortality in idiopathic DCM (OR 
1.62, 95% CI 1.04 - 3.98, p=0.037).
Conclusion. Patients with idiopathic DCM have greater cardiac 
dysfunction than those with familial disease, but mortality is 
similarly high in both groups. Digoxin use without drug level 
monitoring may be associated with increased mortality in idiopathic 
DCM.
S Afr Med J 2011;101:399-404.
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DCM, based on clinical evidence of heart failure associated with left 
ventricular dilatation and a left ventricular ejection fraction <50% 
on echocardiography or cardiac catheterisation.1 Familial DCM was 
defined as the finding that a patient with unexplained DCM had a 
first-degree relative with the condition.10 The selection of the patients 
for inclusion has been described elsewhere.7 The study was approved 
by the University of Cape Town Research Ethics Committee (REC 
Ref. No. 197/96). 
Data collection
All patients had comprehensive clinical assessment. Information 
collected at the time of physical examination included history of 
medical co-morbidity, medications used, and history of alcohol and 
tobacco use. Important clinical parameters including pulse rate, 
blood pressure, oedema, jugular venous pressure (JVP), presence 
of murmurs and crepitations were recorded. Clinical assessment 
was complemented by chest radiography, an electrocardiogram 
(ECG) and detailed two-dimensional and Doppler colour-flow 
echocardiography. Normal values for echocardiographic measurement 
were based on age and body surface area. Cardiac catheterisation was 
performed when appropriate, and tissue obtained at biopsy of right 
ventricular endomyocardium was examined by light microscopy, 
immunohistochemistry and electron microscopy by a pathologist 
with no knowledge of the family history of any patient. 
Statistical analysis
Results of quantitative variables are given as mean (standard deviation 
(SD)). Categorical variables are represented as number and percentage. 
Pearson’s chi-square or Fisher’s exact test was used to compare the 
relative frequency of characteristics between individuals. All p-values 
were two-sided, and a p-value <0.05 was considered significant. 
Kaplan-Meier survival curves were constructed using the product-
limit method, and were compared using the log-rank test. Kaplan-
Meier curves were utilised to visualise the survival experience 
between familial and idiopathic DCM patients, and the focus was 
on mortality rather than time to death, justifying the choice of Cox’s 
logistic regression rather than the Cox proportional hazards model. 
Age-, gender- and race-adjusted survival curves for the general South 
African population were derived and compared with the Kaplan-
Meier survival rates for the patients with idiopathic or familial 
DCM using the chi-square test. Kaplan-Meier survival curves were 
constructed using STATA version 9.0 (STATA Corporation, College 
Station, TX, USA). Univariate and multivariate logistic regression 
analysis was used to determine predictors of death.
Results
Clinical characteristics at presentation
A total of 120 patients were studied, comprising 80 patients with 
idiopathic DCM and 40 familial cases from 29 families. The familial 
DCM patients had a younger age at diagnosis compared with the 
idiopathic DCM patients, with mean ages of 25.6 (SD 15.1) years and 
39.1 (SD 12.6) years (p=0.001), respectively, as reported elsewhere.7 
The clinical symptoms and signs of patients with familial DCM 
were similar to those of patients with idiopathic DCM (Table I). ECG 
findings were similar between the two groups, with the exception 
of T-wave inversion, which was found more commonly in familial 
patients compared with idiopathic DCM patients (35 (87.5%) v. 55 
(68.8%), respectively, p=0.014), and pathological Q waves, which 
were found more commonly in idiopathic DCM (32.5%) than in 
familial cases (12.5%) (p=0.028). Patients with idiopathic DCM were 
more likely to have radiographic cardiomegaly, which was found 
in 75/80 (93.8%) of patients with idiopathic DCM compared with 
28/40 (70%) of familial cases (p=0.020). The radiographic findings 
were corroborated by echocardiography, which showed patients 
with idiopathic DCM to have significantly larger left ventricular 
end-diastolic dimensions (LVEDD) (p=0.001), lower left ventricular 
ejection fraction (LVEF) (p=0.026) and fractional shortening (LVFS) 
(p=0.048) than the familial cases (Table I). 
At cardiac catheterisation, the only difference noted was in the 
LVEF, which was found to be lower in patients with idiopathic DCM 
compared with familial cases (26.2 (SD 9.7) v. 31.07 (SD 15.63), 
p=0.032). There were no differences between the two groups in 
histological characteristics on light microscopy. There were also no 
significant differences between familial and idiopathic DCM patients 
in relation to risk factors for cardiovascular disease, lung disease, HIV 
infection or stroke.
Medical therapy and outcome at last  
follow-up visit
Familial and idiopathic DCM patients were on similar treatments. 
However, beta-blockers (p=0.007) and digoxin (p=0.028) were more 
commonly prescribed for patients with idiopathic DCM (Table II). 
There were no differences in mortality, clinical features, cardiovascular 
complications or utilisation of orthotopic heart transplantation 
between the two groups at last follow-up (Table III).
On univariate logistic regression analysis, factors that increased 
the likelihood of death in both familial and idiopathic cases were an 
increased LVEDD (p=0.038) and LVESD (p=0.049), an elevated JVP 
(above the angle of the jaw) at the initial visit (p=0.028), pulmonary 
hypertension (p=0.025), lack of orthotopic heart transplantation 
(p=0.004), and symptomatic heart failure with New York Heart 
Association (NYHA) functional class III and IV symptoms at the 
last visit (p=0.017), as shown in Table IVa. On multivariate analysis, 
significant predictors of mortality included lack of orthotopic heart 
transplantation (odds ratio (OR) 4.7, 95% confidence interval (CI) 
1.3 - 72.6, p=0.026) and NYHA class III and IV symptoms at the last 
visit (OR 3.8, 95% CI 1.3 - 48.5, p<0.001). 
The use of digoxin in patients with idiopathic DCM was associated 
with increased mortality (OR 1.6, 95% CI 1.0 - 3.9, p=0.037), but this 
was not the case in the familial DCM group (Table IVb). 
Survival analysis
Fig. 1A shows the Kaplan-Meier survival analysis, with no survival 
difference between the idiopathic and familial DCM groups (p=0.739). 
The mortality rate at the end of a median follow-up period of 5 years 
was 40% in both groups (Table III).
Fig. 1B compares survival of the idiopathic DCM patients with 
controls matched for age, gender and race in the general South 
African (SA) population, showing that mortality is higher in the 
idiopathic DCM group (p=0.001). In Fig. 1C, survival of the familial 
DCM cohort is compared with the matched members of the South 
African population, and there is a strong trend towards increased 
mortality in the familial DCM group (p=0.053). Fig. 1D compares 
transplant-free survival between idiopathic and familial DCM, 
showing no difference between the two groups (p=0.986). Fig. 1E 
compares transplant-free survival between idiopathic DCM patients 
and controls matched for age, gender and race in the SA population 
(p<0.001), and Fig. 1F compares transplant-free survival in familial 
DCM patients and controls matched for age, gender and race in the 
SA population (p<0.001). Survival free of transplantation is worse for 
both groups when compared with the general population.
Discussion
Several important observations emerge from this study of 80 idiopathic 
and 40 familial DCM patients. Firstly, despite the more favourable age 
and left ventricular function of the patients with familial DCM, there 
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Table I. Clinical, radiographic, electrocardiographic and echocardiographic features at presentation
 Idiopathic DCM (N=80) Familial DCM (N=40) p-value
Clinical characteristics 
NYHA FC (N (%))
   Class 1 and 2 19 (23.8) 11 (27.5)
   Class 3 and 4 61 (76.3) 29 (72.5) 0.110
Dyspnoea (N (%)) 79 (98.8) 36 (90) 0.295
Fatigue (N (%)) 79 (98.8) 40 (100) 0.596
Angina/chest pain (N (%)) 9 (11.3) 4 (10) 0.489
Palpitations (N (%)) 19 (23.8) 10 (25) 0.513
Heart rate (/min) (mean (SD)) 94.89 (19.53) 95.61 (28.32) 0.496
Blood pressure, systolic  101.78 (18.11) 100.10 (14.94) 0.397
Blood pressure, diastolic 64.37 (12.82) 70.29 (13.45) 0.289
(mmHg) (mean (SD))
Pedal oedema (N (%)) 59 (73.8) 29 (72.5) 0.583
JVP height (N (%))
   Below 3cm 23 (28.7) 11 (27.5)
   3cm to angle of jaw 28 (35.0) 11 (27.5)
   Above angle of the jaw 29 (36.3) 18 (45) 0.337
Murmur (N (%))
   No murmur 18 (22.5) 12 (30)
   MR 35 (43.8) 13 (32.5)
   MR + TR 24 (30) 14 (35)
   ESM 3 (3.8) 1 (2.4) 0.220
S3 gallop (N (%)) 56 (70) 27 (67.5) 0.695
Basal crepitations (N (%)) 39 (48.8) 24 (60) 0.165
Radiographic features 
Cardiothoracic ratio >50% (N (%)) 75 (93.8) 28 (70) 0.020
Radiographic pulmonary oedema (N (%)) 43 (53.8) 24 (60) 0.412
Electrocardiographic features 
Heart rate (mean (SD)) 92.85 (19.53) 96.58 (23.02) 0.498
Sinus rhythm (N (%)) 60 (75) 26 (65) 0.218
QRS abnormalities present (N (%)) 36 (45) 14 (35) 0.399
Increased voltage (N (%)) 40 (50) 22 (55) 0.583
Presence of pathological Q waves (N (%)) 26 (32.5) 5 (12.5) 0.028
Left atrial hypertrophy (N (%)) 19 (23.8) 8 (20) 0.318
Left bundle-branch block morphology (N (%)) 29 (36.3) 7 (17.5) 0.123
Right bundle-branch block morphology (N (%)) 2 (2.5) 0 (0) 0.518
Left ventricular hypertrophy (%) 28 (35) 12 (30) 0.243
Right ventricular hypertrophy (%) 1 (1.3) 0 (0) 0.721
PR prolongation present (%) 2 (2.5) 0 (0) 0.311
T-wave inversion (%) 55 (68.8) 35 (87.5) 0.014
Arrhythmia present (%)
   No arrhythmia 60 (75) 26 (65)
   Atrial fibrillation 16 (20) 10 (25)
   Atrial flutter 0 (0) 1 (2.5)
   Ventricular tachycardia 1 (1.3) 2 (5)
   Paced rhythm 3 (3.8) 1 (2.5) 0.179
QRS duration (ms) (mean (SD)) 112.07 (11.93) 109.98 (12.31) 0.107
Echocardiographic features
Interventricular septal thickness (systole) (mean (SD)) 1.04 (0.36) 1.15 (0.39) 0.469
Interventricular septal thickness (diastole) (mean (SD)) 0.92 (0.30) 1.08 (0.36) 0.389
Left ventricular posterior free wall thickness 1.10 (0.41) 1.18 (0.42) 0.292
(systole) (mean (SD))
Left ventricular posterior free wall thickness 0.92 (0.32) 0.96 (0.30) 0.593
(diastole) (mean (SD))
Left ventricular dimension (systole) (mean (SD)) 5.54 (1.31) 5.42 (2.13) 0.602
Left ventricular dimension (diastole) (mean (SD)) 6.84 (1.37) 6.21 (1.13) 0.001
Left ventricular ejection fraction (mean (SD)) 24.68 (11.50) 28.01 (10.51) 0.026
Left ventricular fractional shortening (mean (SD)) 12.10 (5.99) 14.81 (7.86) 0.048
DCM = dilated cardiomyopathy; NYHA FC = New York Heart Association functional class; SD = standard deviation; MR = mitral regurgitation; MR + TR = mitral regurgitation plus tricuspid 
regurgitation; ESM = ejection systolic murmur. 
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Table II. Medical therapy at follow-up
Medical therapy at last follow-up visit Idiopathic DCM (N=80) Familial DCM (N=40) p-value
Furosemide (N (%)) 78 (97.5) 37 (92.5) 0.116
ACE-I or ARB (N (%)) 80 (100) 39 (97.5) 0.466
Beta-blocker (N (%)) 76 (95) 30 (75) 0.007
Digoxin (N (%)) 70 (87.5) 26 (65) 0.028
Spironolactone (N (%)) 62 (78.5) 25 (62.5) 0.072
Calcium channel blocker (N (%)) 0 (0) 3 (7.5) 0.169
Warfarin (N (%)) 22 (27.5) 12 (30) 0.445
DCM = dilated cardiomyopathy; ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker. 
was a high mortality (40%) after a median follow-up of 5 years, which 
was similar to patients with idiopathic DCM. Second, the presence of 
symptoms of heart failure was the most important clinical predictor 
of mortality, which was significantly reduced by intervention with 
orthotopic heart transplantation. Thirdly, and of concern, the use of 
digoxin in patients with idiopathic DCM appeared to be associated 
with excess mortality.  
We show that patients with idiopathic DCM have greater left 
ventricular dimension in systole and diastole on echocardiography, 
more radiographic cardiomegaly, and lower contractile capacity 
on echocardiography and cardiac catheterisation. ECGs revealed a 
greater prevalence of pathological Q waves in idiopathic DCM in the 
absence of coronary artery disease. Similarly, Grünig and colleagues 
have shown that ECG ST-segment and T-wave abnormalities occurred 
more frequently in familial than in idiopathic DCM.11 However, other 
authors have failed to demonstrate ECG differences between familial 
and idiopathic cases of DCM.12-14 ECG features are not sufficiently 
specific or sensitive to distinguish between familial DCM and 
idiopathic DCM, and are not useful for clinical classification. In our 
study, as with most comparisons of familial DCM with idiopathic 
DCM,12,15,16 there were no reliable clinical or morphological features 
capable of distinguishing between familial and non-familial forms of 
DCM, apart from a younger age of onset.7
We found that persistent symptoms of heart failure associated 
with NYHA functional class III or IV features are the most powerful 
predictor of mortality in both idiopathic and familial DCM. Similarly, 
Limongelli and colleagues showed that,  in a cohort of 48 adolescents 
with idiopathic DCM, NYHA functional class III and IV, pro-
brain natriuretic peptide and ECG left atrial enlargement were 
the most important predictors of adverse outcomes.17 Pasotti and 
co-investigators reported on a group of 27 consecutive patients 
with DCM and lamin A/C gene mutations and found that NYHA 
functional class III and IV and competitive sports were the significant 
predictors of all cardiovascular events, including death.18 Other 
important predictors of mortality in DCM patients include advanced 
age, protodiastolic gallop, failure of the myopathic ventricle to 
respond to inotropic stimulation, ventricular arrhythmias, prolonged 
ECG QRS duration, reduced left ventricular function, and late 
gadolinium enhancement on cardiovascular magnetic resonance 
imaging.19,20 
The annual mortality rate for patients with heart failure is 10 - 13%, 
which is similar to the mortality rate of 50% after a median follow-
up period of 5 years that was found in this study.21 However, while 
the rate of progression is variable and influenced by several factors, 
symptomatic patients experience progressive deterioration, and 10 - 
40% of symptomatic patients with heart failure may die within a 
Table III. Complications, treatment and outcome data
Outcome data Idiopathic DCM (N=80) Familial DCM (N=40) p-value
Median duration of follow-up (yrs) (IQR) 5.58 (1.42 - 10.41) 4.58 (1.33 - 14.8) 0.063
Death at the end of the median follow-up period (N (%)) 32 (40) 16 (40) 0.595
Chronic heart failure (N (%)) 63 (78.8) 32 (80) 0.515
Intracardiac clot (N (%)) 3 (3.8) 2 (5) 0.496
Embolic phenomena (N (%)) 2 (2.5) 1 (2.5) 0.505
Pulmonary hypertension (N (%)) 0 (0) 1 (2.5) 0.466
Implantable cardioverter defibrillator insertion (N (%)) 1 (1.3) 1 (2.5) 0.453
Permanent pacemaker insertion (N (%)) 2 (2.5) 1 (2.5) 0.513
Cardiac resynchronisation therapy/biventricular pacing (N (%)) 2 (2.5) 3 (7.5) 0.108
Orthotopic heart transplantation (N (%)) 15 (18.8) 11 (27.5) 0.116
NYHA FC at last visit (N (%))
   Class 1 and 2 50 (62.5) 17 (42.5)
   Class 3 and 4 30 (37.5) 23 (57.5) 0.205
DCM = dilated cardiomyopathy; IQR = interquartile range; NYHA FC = New York Heart Association functional class.
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year.22 It is therefore important that clinicians pay particular attention 
to medical and surgical management of persistent symptoms in 
DCM patients, with the aim of escalating management including 
use of cardiac resynchronisation therapy and heart transplantation, 
as NYHA class III and IV symptoms remain powerful predictors of 
mortality. The medical history is therefore the most important tool 
for assessment of adequacy of treatment in DCM.
The patients in our study were on good medical treatment, with 
more than 60% simultaneously receiving an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker, a beta-blocker, 
spironolactone and digoxin. However, we found that beta-blockers 
and digoxin were more commonly prescribed in the idiopathic 
DCM group. The increased use of beta-blockers and digoxin in the 
idiopathic DCM group may reflect the fact that this group of patients 
had more severe disease, as evidenced by a greater LVEDD and lower 
LVEF. It has been observed by others that patients with familial DCM 
are less intensively treated with evidence-based therapies for heart 
failure than patients with sporadic DCM.16 
Interestingly, digoxin appears to be a significant predictor of 
mortality in idiopathic DCM but not in familial DCM. Evidence 
from old clinical trials conducted before the introduction of beta-
blockers for the treatment of heart failure supports the use of digoxin 
in patients with left ventricular systolic dysfunction for the treatment 
of heart failure, particularly those with advanced symptoms.23,24 There 
is, however, no evidence that digoxin improves survival – and in 
fact it may worsen outcomes in DCM patients. The effect of digoxin 
therapy differs between men and women, being associated with an 
increased risk of death from any cause among women with heart 
failure and depressed left ventricular systolic function.25 The DIG 
trial, a study of almost 6 800 patients with symptomatic heart failure 
and a LVEF below 45% and who were in sinus rhythm, assigned 
randomly to receive either digoxin or placebo, showed that after 3 
years of follow-up: (i) there was no difference in survival between the 
digoxin and placebo groups; (ii) the patients on digoxin had reduced 
symptoms and hospitalisation for heart failure; (iii) patients on 
digoxin had significant increase in non-heart failure deaths, including 
deaths from arrhythmia, particularly in women; and (iv) lower serum 
digoxin levels correlated with survival (the ideal serum level is 0.65 - 
1.0 nmol/l).26,27 Serum levels of digoxin were not monitored in our 
study. The results of our retrospective analysis suggest that clinicians 
should refrain from blanket prescription of digoxin for all DCM 
patients without monitoring digoxin levels. 
Our findings have important implications for clinical practice 
and research. First, the presence of symptoms of heart failure with 
mild cardiac structural and functional abnormalities in relatives of 
patients with DCM is associated with a poor prognosis. Second, 
the study emphasises the need to refer patients with DCM and 
persistent symptoms of effort intolerance for evaluation for life-saving 
interventions such as heart transplantation. There is anecdotal evidence 
that patients with DCM are not referred in a timely manner for heart 
transplantation in South Africa. Finally, there is a need to review the 
use of digoxin in patients with heart failure in view of the mortality 
risk that has been shown in this study. It is prudent to monitor digoxin 
levels, together with serum potassium and renal function, in all patients 
in view of the correlation of levels with mortality.27 
While this study has important findings for clinical practice, it 
also has several limitations. First, generalisation of findings may be 
limited by the relatively small sample size. Second, its population 
is dominated by patients with familial DCM, which is typical of a 
tertiary referral clinic. Finally, the study has the drawbacks imposed 
by a retrospective design.
In conclusion, DCM due to familial and non-familial causes is 
associated with a high mortality despite modern medical and surgical 
therapy. Patients with persistent symptoms of heart failure despite 
Table IVb. Logistic regression analysis for predictors of mortality in idiopathic DCM
                 Univariate analysis                Multivariate analysis
Characteristic OR (95% CI) p-value OR (95% CI) p-value
Use of digoxin (yes v. no) 4.267 (1.161 - 15.676) 0.008 1.617 (1.036 - 3.984) 0.037
Bold p-values denote statistical significance.
DCM = dilated cardiomyopathy; OR = odds ratio; CI = confidence interval.
Table IVa. Logistic regression analysis for predictors of mortality in familial and idiopathic DCM
                 Univariate analysis                  Multivariate analysis
Characteristic OR (95% CI) p-value OR (95% CI) p-value
LVESD 1.764 (1.133 - 2.747) 0.038 0.955 (0.770 - 1.184) 0.674
LVEDD 1.719 (1.129 - 2.618) 0.049 1.117 (0.889 - 1.403) 0.341
JVP (>AOJ v. <AOJ) 5.600 (1.202 - 26.095) 0.028 1.808 (0.256 - 12.777) 0.553
Pulmonary hypertension 
(yes v. no)
3.586 (1.086 - 13.660) 0.025 1.401 (0.941 - 2.360) 0.646
Orthotopic heart 
transplantation (no v. yes)
8.053 (0.954 - 67.970) 0.004 4.717 (1.306 - 72.600) 0.026
NYHA FC at last visit 
(class 3 or 4 v. class 1 or 2)
12.473 (1.576 - 98.703) 0.017 3.848 (1.305 - 48.469) <0.001
Bold p-values denote statistical significance.
DCM = dilated cardiomyopathy; LVESD = left ventricular end-systolic dimension; LVEDD = left ventricular end-diastolic dimension; JVP = jugular venous pressure; AOJ = angle of jaw; NYHA 
FC = New York Heart Association functional class; OR = odds ratio; CI = confidence interval. 
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optimal medical therapy should be referred for orthotopic heart 
transplantation and other life-saving interventions. 
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Fig. 1. Kaplan-Meier survival plots. A = comparison of survival in idiopathic DCM patients compared with familial DCM 
patients (p=0.739); B = comparison of survival in idiopathic DCM patients compared with controls matched for age, gender 
and race in the South African population (p=0.001); C = comparison of survival in familial DCM patients compared with 
controls matched for age, gender and race in the SA population (p=0.053); D = comparison of transplantation-
free survival in idiopathic DCM patients compared with familial DCM patients (p=0.986); E = comparison of 
transplantation-free survival in idiopathic DCM patients compared with controls matched for age, gender and race 
in the SA population (p<0.001); and F = comparison of transplantation-free survival in familial DCM patients 
compared with controls matched for age, gender and race in the SA population (p<0.001).
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